A DNA vaccine containing DCs loaded with plasmids encoding chimeric rat/human HER2 was able to induce T-cell mediated immunity in patients with pancreatic and HER2+ breast cancer with confinement of tumor growth and overcoming the suppressor effects of regulatory T-cells (Tregs), IL-10, and TGF-β (70). Here, ERBB2 is linked to breast cancer.